Latest revenue
$10.4M
as of 2026-03-31
Latest net income
$1.9M
as of 2026-03-31
Net margin
18.7%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $91.6M
- Enterprise value
- $91.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $10.25
- 52-wk low
- $4.52
- Beta
- —
- Shares out
- 9.0M
5-year trend
What this company does
ITEM 1 — BUSINESS Summary ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. The Company's practical, science-based solutions help prevent calf scours, one of the most prevalent diseases in neonatal calves worldwide that accounts for 30-40% of pre-weaning mortality in many production systems. The Company’s primary product line, First Defense®, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other…
AI summary unavailable — showing raw filing excerpt
Generated from ICCC's filing dated 2026-03-30
Key risks
ITEM 1A — RISK FACTORS We caution you that our business and operations are subject to a number of risks and uncertainties. The factors listed below are important factors that could cause our actual results to differ materially from our historical results and from projections in forward-looking statements contained in this report. Other factors that we do not anticipate, or that we do not consider material based on currently available information, may also have an adverse effect on our results. Financial Risks Gross margin on product sales: We consider gross profit as a percentage of product sales (gross margin) to be a key measure of our overall efficiency of production and of our ability…
AI summary unavailable — showing raw filing excerpt
Generated from ICCC's filing dated 2026-03-30
Profitability
Gross margin
41.4%
38.1%Operating margin
6.0%
196.4%Net margin
-3.8%
53.8%Return on equity
-3.8%
51.0%Return on assets
-2.4%
48.9%Leverage
Debt / equity
0.57×
10.5%Long-term debt / equity
0.28×
15.8%Debt / assets
36.4%
6.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $10.4M | +28.4% | $1.9M | +34.2% | 18.7% |
Q4 2025 2025-12-31 | $7.6M | -1.6% | $-2.8M | -653.7% | -37.4% |
Q3 2025 2025-09-30 | $5.5M | -8.4% | $-139.7K | +80.1% | -2.5% |
Q2 2025 2025-06-30 | $6.4M | +17.8% | $501.9K | +132.8% | 7.8% |
Q1 2025 2025-03-31 | $8.1M | +11.2% | $1.4M | +430.5% | 17.9% |
Q4 2024 2024-12-31 | $7.8M | — | $514.6K | — | 6.6% |
Q3 2024 2024-09-30 | $6.0M | +11.4% | $-701.7K | +25.4% | -11.7% |
Q2 2024 2024-06-30 | $5.5M | +54.9% | $-1.5M | -11.0% | -28.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on ICCC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$102.0K
Insider selling
$0
Net activity
+$102.0K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ICCC
Institutional value
$3.7M
Total shares held
579.7K
Distinct holders
15
-11 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 260.3K | $1.6M | — | New |
| 2 | DIMENSIONAL FUND ADVISORS LP | 56.0K | $354.7K | +1.7K (+3.2%) | Added |
| 3 | Steadtrust LLC | 54.4K | $344.2K | -2.4K (-4.2%) | Trimmed |
| 4 | VANGUARD FIDUCIARY TRUST CO | 42.7K | $270.1K | — | New |
| 5 | Mesirow Financial Investment Management, Inc. | 42.5K | $268.9K | +6.0K (+16.4%) | Added |
| 6 | Strategic Financial Services, Inc. | 37.0K | $234.2K | +0 (+0.0%) | No change |
| 7 | HighTower Advisors, LLC | 24.4K | $154.2K | +5.0K (+25.8%) | Added |
| 8 | BlackRock, Inc. | 18.2K | $115.1K | +1.9K (+11.9%) | Added |
| 9 | Militia Capital Management LLC | 18.0K | $113.9K | — | New |
| 10 | Essex Financial Services, Inc. | 11.0K | $69.6K | +0 (+0.0%) | No change |
| 11 | BAILARD, INC. | 10.1K | $63.9K | — | New |
| 12 | HM PAYSON & CO | 4.0K | $25.3K | +0 (+0.0%) | No change |
| 13 | UBS Group AG | 1.1K | $7.0K | -498 (-30.9%) | Trimmed |
| 14 | WELLS FARGO & COMPANY/MN | 1 | $4 | +0 (+0.0%) | No change |
| 15 | Capital Advisors, Ltd. LLC | 98 | $1 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ICCC's latest filing finishes processing.